The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why is the German experience with commercial CAR T inferior to published study data?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Wolfgang Bethge, University Hospital Tübingen, Tübingen, DE. We asked, Why is the German experience with commercial CAR T inferior to published study data?

Why is the German experience with commercial CAR T inferior to published study data?

In this video, Bethge discusses the real-world data on the chimeric antigen receptor (CAR) T-cell products, axi-cel and tisa-cel, for patients with relapsed or refractory large B-cell lymphomas from a German registry-based retrospective study. He describes the reasons why progression-free survival and relapse rate were inferior in this trial compared to the pivotal studies, highlighting patient selection as an important factor.

Share: